Zelluna names MaSTherCell as CDMO to support immunotherapy development

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/CIPhotos)
(Image: Getty/CIPhotos)
Zelluna Immunotherapy has partnered with the CDMO MasSTherCell to develop its T-cell receptor (TCR) adoptive cell therapy platform with clinical trials expected to begin in 2019.

The biotechnology company Zelluna, which specializes in TCR-based immunotherapies for solid tumors, has appointed MaSTherCell as its contract development and manufacturing (CDMO) partner.

The partnership is a milestone for Zelluna as it pursues clinical trials and commercialization of its TCR-T multiple targets program, according to the company. Zelluna expects to begin trials in 2019.

“The objective of the collaboration with MaSTherCell is to enhance the GMP manufacturing process and deliver an optimized industrial manufacturing process that can deliver Zelluna TCR-T products for clinical development and eventually commercial distribution, with a broad geographic footprint,”​ Miguel Forte, CEO, Zelluna, told us.

MaSTherCell will initially perform a diagnostic assessment of the existing Zelluna GMP manufacturing process at the facilities at Oslo University Hospital. It will then develop a process development plan to further optimize and automate the current manufacturing process, Forte explained.

“Applying a quality by design (QbD) approach, we know that our development effort will not only fast-track the development of Zelluna’s products, but also prepare the latter clinical phases (III and IV),”​ said Denis Bedoret, managing director, MaSTherCell, who told us the company has worked well with Zelluna in the past.

Bedoret said the next step is to finalize the development plan and to select technologies. “We are today evaluating the equipment candidates for the trials,”​ he explained. “Then the development operations will start with the first runs.”

Choosing a CDMO

In selecting a CDMO with which to partner, Forte said relevant experience and know-how, capacity, and cultural fit are key to the assessment.

“From Zelluna’s point of view, MaSTherCell presented an extensive experience in process development and manufacturing of T cell based therapies including engineered TCR targeted T cell products,” ​he explained, adding that Zelluna expects a “fruitful​” collaboration with MaSTherCell.

Forte said it was also important that current and future manufacturing capacity would able to support short-term manufacturing of clinical supplies and potentially medium to long-term commercial supplies. 

Bedoret added that MaSTherCell has “a unique client-oriented business model based on transparency,” ​and believes that this was a key decision criterion.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more